HRP20211908T1 - Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa - Google Patents
Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa Download PDFInfo
- Publication number
- HRP20211908T1 HRP20211908T1 HRP20211908TT HRP20211908T HRP20211908T1 HR P20211908 T1 HRP20211908 T1 HR P20211908T1 HR P20211908T T HRP20211908T T HR P20211908TT HR P20211908 T HRP20211908 T HR P20211908T HR P20211908 T1 HRP20211908 T1 HR P20211908T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- cnp variant
- seq
- nos
- use according
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims 11
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 title 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 title 1
- 210000000845 cartilage Anatomy 0.000 claims 7
- 230000007850 degeneration Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 210000003127 knee Anatomy 0.000 claims 3
- 108010041390 Collagen Type II Proteins 0.000 claims 2
- 102000000503 Collagen Type II Human genes 0.000 claims 2
- 108050006400 Cyclin Proteins 0.000 claims 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 2
- 102000016611 Proteoglycans Human genes 0.000 claims 2
- 108010067787 Proteoglycans Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- 102000016284 Aggrecans Human genes 0.000 claims 1
- 108010067219 Aggrecans Proteins 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 101800000938 Chondrocalcin Proteins 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 206010060820 Joint injury Diseases 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010061592 cardiac fibrillation Diseases 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002600 fibrillogenic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000004247 hand Anatomy 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000008409 synovial inflammation Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 210000000707 wrist Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| EP16852866.9A EP3386531B1 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211908T1 true HRP20211908T1 (hr) | 2022-03-04 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211908TT HRP20211908T1 (hr) | 2015-12-08 | 2016-12-08 | Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (enExample) |
| EP (2) | EP3386531B1 (enExample) |
| JP (1) | JP7104625B2 (enExample) |
| KR (1) | KR20180088459A (enExample) |
| CN (1) | CN108697766A (enExample) |
| AU (2) | AU2016365751B2 (enExample) |
| CA (1) | CA3007315A1 (enExample) |
| DK (1) | DK3386531T3 (enExample) |
| ES (1) | ES2901769T3 (enExample) |
| HR (1) | HRP20211908T1 (enExample) |
| HU (1) | HUE057083T2 (enExample) |
| IL (1) | IL259690B2 (enExample) |
| MX (1) | MX2018006986A (enExample) |
| PL (1) | PL3386531T3 (enExample) |
| PT (1) | PT3386531T (enExample) |
| RU (1) | RU2759679C2 (enExample) |
| WO (1) | WO2017100400A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| BR112018011008A2 (en) | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders A/S | low npr-c binding controlled release cnp agonists |
| EP3400022A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
| MX2018008050A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. |
| HUE062117T2 (hu) | 2016-09-29 | 2023-09-28 | Ascendis Pharma Growth Disorders As | Kombinációs terápia szabályozott felszabadulású CNP agonistákkal |
| BR112020021966A2 (pt) * | 2018-04-27 | 2021-01-26 | Remy Biosciences, Inc. | dispositivos médicos, veículos de liberação e fabricação dos mesmos |
| WO2020165081A1 (en) * | 2019-02-11 | 2020-08-20 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| EP4337957A1 (en) * | 2021-05-11 | 2024-03-20 | Texas Tech University System | Targeted selenium conjugates as countermeasures for pathogenic viruses and cells |
| MX2024007052A (es) * | 2021-12-07 | 2024-09-05 | Biomarin Pharm Inc | Terapia de dnc. |
| AR130935A1 (es) | 2022-11-02 | 2025-02-05 | Novo Nordisk As | Compuestos de cnp |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024194300A1 (en) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| EP3620530A1 (en) | 2004-03-31 | 2020-03-11 | Kazuwa Nakao | Composition for increasing body height |
| ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| AR069409A1 (es) * | 2007-11-21 | 2010-01-20 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
| HRP20161739T1 (hr) | 2009-05-20 | 2017-03-10 | Biomarin Pharmaceutical Inc. | VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa |
| CA2823066A1 (en) * | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 KR KR1020187019166A patent/KR20180088459A/ko active Pending
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019505486A (ja) | 2019-02-28 |
| AU2016365751B2 (en) | 2023-12-21 |
| PL3386531T3 (pl) | 2022-02-28 |
| WO2017100400A2 (en) | 2017-06-15 |
| DK3386531T3 (da) | 2022-01-03 |
| EP4019038A2 (en) | 2022-06-29 |
| RU2018124600A3 (enExample) | 2020-01-13 |
| AU2024201852A1 (en) | 2024-04-11 |
| KR20180088459A (ko) | 2018-08-03 |
| EP3386531B1 (en) | 2021-10-13 |
| AU2016365751A1 (en) | 2018-06-21 |
| CA3007315A1 (en) | 2017-06-15 |
| IL259690A (en) | 2018-07-31 |
| IL259690B2 (en) | 2023-02-01 |
| HUE057083T2 (hu) | 2022-04-28 |
| ES2901769T3 (es) | 2022-03-23 |
| WO2017100400A3 (en) | 2017-10-26 |
| RU2018124600A (ru) | 2020-01-13 |
| IL259690B (en) | 2022-10-01 |
| US11202819B2 (en) | 2021-12-21 |
| US20190247467A1 (en) | 2019-08-15 |
| CN108697766A (zh) | 2018-10-23 |
| EP3386531A2 (en) | 2018-10-17 |
| RU2021132347A (ru) | 2022-03-24 |
| RU2759679C2 (ru) | 2021-11-16 |
| PT3386531T (pt) | 2021-12-29 |
| EP4019038A3 (en) | 2022-09-28 |
| JP7104625B2 (ja) | 2022-07-21 |
| US20220160836A1 (en) | 2022-05-26 |
| MX2018006986A (es) | 2018-09-05 |
| US12214015B2 (en) | 2025-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211908T1 (hr) | Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa | |
| JP2019505486A5 (enExample) | ||
| MY154865A (en) | Wearing article | |
| CA2857686C (en) | Use of growth hormone fragments | |
| PH12019501900A1 (en) | Treatment of hidradenitis suppurativa | |
| CN103622013A (zh) | 一种供关节炎患者食用含骨胶原肽的食品配方 | |
| ES2579828T3 (es) | Composición para la prevención y el tratamiento de la artritis reumatoide | |
| BR112020004935A8 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
| Góes et al. | Gait characteristics of women with fibromyalgia: a premature aging pattern | |
| Suthar et al. | Orthopaedic aspect of anatomy and radiology of proximal femur | |
| Habibi et al. | Idiopathic chondrolysis in a child: think beyond JIA. | |
| MD3906F1 (en) | Method for treating the neurotic enuresis to children | |
| Luo et al. | Finite element analysis of the biomechanical effects of manipulation of lower limb hyperextension on the sacroiliac joint | |
| Rogers | Analysis of Colles's Fracture | |
| WEBER et al. | Fibrous Replacement of the Deltoid Muscle: A Remediable Cause of Abduction Contracture of the Shoulder in Scleroderma. | |
| Murlimanju et al. | Clinically oriented anatomy of the frozen shoulder | |
| Henner et al. | Recurrent Legg-Perthes-Calvé disease | |
| Zha et al. | Z-plasty for severe gluteal muscle contracture in children | |
| Nataliia et al. | THE SHOULDER PAIN TREATMENT | |
| CN204812197U (zh) | 一种老年人防摔骨折保护裤 | |
| CN202236861U (zh) | 一种预防和治疗风湿病的护膝 | |
| CN202802076U (zh) | 多功能腕指康复板 | |
| Bjornstad | Description of a new genus and species of Psebiini Lacordaire, 1868 from South Africa (Coleoptera: Cerambycidae: Cerambycinae) | |
| Javaid et al. | Comparison of laparoscopic versus open inguinal hernioplasty | |
| Joseph et al. | Fractures in boys with Duchenne muscular dystrophy and their relationship to age |